WOMEN'S HEALTH: U.S. MARKETS FOR OSTEOPOROSIS MANAGEMENT PRODUCTS
129 Pages | 30 Exhibits | 2008 Analysis | Forecasts Through 2010
In 2007, the United States (U.S.) market for osteoporosis management products totaled approximately $7.6 billion.
Sales of these products are expected to increase at a compound annual rate of 6.6%, reaching an estimated $9.3
billion in the year 2010.
This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets,
competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever
U.S. Surgeon General's report on the nation's bone health, by the year 2020 one out of two Americans over the age of
50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated
to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing
Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers,
bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs
such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such
as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene
therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.
TABLE OF CONTENTS:
i. Osteoporosis Incidence and Prevalence
ii. Osteoporosis Diagnosis and Management
a. Bone Densitometry
b. Biochemical Markers
c. Osteoporosis Treatments
iii. Market Analysis
a. Bone Densitometry Systems
b. Biochemical Markers
c. Hormone Replacement Therapy and Osteoporosis Drugs
i. Hormone Replacement Therapy Drugs
ii. Osteoporosis Drugs
Exhibit ES-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
Exhibit ES-3: Total Bone Densitometry Systems, Market Forecast, 2005-2010
Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
Exhibit ES-5: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
Exhibit ES-6: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
Exhibit ES-7: Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit ES-8: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
1. OSTEOPOROSIS MANAGEMENT PRODUCTS MARKET
1.1 Overview of Osteoporosis
1.1.1 Incidence, Prevalence, and Cost
1.1.2 Types of Osteoporosis
1.1.3 Risk Factors
1.2.1 Bone Densitometry
18.104.22.168 Products, by Application
22.214.171.124.1 Hospital-Based Densitometry Systems
126.96.36.199.2 Office-Based Densitometry Systems
188.8.131.52.3 Software-Based Systems
184.108.40.206 Products and Suppliers
220.127.116.11.1 CooperSurgical/The Cooper Companies
18.104.22.168.2 GE Healthcare/General Electric Company
22.214.171.124 Market Analysis
126.96.36.199 Competitive Analysis
1.2.2 Biochemical Markers
188.8.131.52 Products and Suppliers
184.108.40.206.1 Beckman Coulter
220.127.116.11.2 Roche Diagnostics/F. Hoffmann- La Roche/Roche Holding
18.104.22.168.3 Inverness Medical Innovations
22.214.171.124.4 Orion Diagnostica Oy/Orion Group
126.96.36.199 Market Analysis
188.8.131.52 Competitive Analysis
1.3.1 Antiresorptive Drugs
184.108.40.206 Selective Estrogen Receptor Modulators
1.3.2 Bone-Forming Drugs
220.127.116.11 Sodium Fluoride
18.104.22.168 Parathyroid Hormone
1.3.3 Dual-Acting Drug
1.3.4 Other Treatments
22.214.171.124 Monoclonal Antibodies
126.96.36.199 Cathepsin K Inhibitors
188.8.131.52 Gene Therapy
184.108.40.206 Statin Drugs
220.127.116.11 Selective Androgen Receptor Modulators
1.3.5 Market Analysis
18.104.22.168 Hormone Replacement Therapy Drugs
22.214.171.124 Osteoporosis Drugs
1.3.6 Competitive Analysis
1.3.7 Combined Market Analysis
Exhibit 1-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit 1-2: Prevalence of Osteoporosis and Low Bone Mass in Men and Women Age 50 and Older, by Ethnicity
Exhibit 1-3: Types of Osteoporosis
Exhibit 1-4: Leading Risk Factors for Osteoporosis
Exhibit 1-5: Comparison of Bone Densitometry and Osteoporosis Biochemical Marker Screenings
Exhibit 1-6: Imaging Technologies Used to Diagnose Osteoporosis
Exhibit 1-7: 2008, Selected Bone Densitometry Systems
Exhibit 1-8: Bone Densitometry Hospital Systems, Market Forecast, 2005-2010
Exhibit 1-9: Bone Densitometry Office Systems, Market Forecast, 2005-2010
Exhibit 1-10: Total Bone Densitometry Systems, Market Forecast, 2005-2010
Exhibit 1-11: 2007, Bone Densitometry Systems Market, Share by Supplier
Exhibit 1-12: Comparison of Bone Remodeling Biochemical Markers
Exhibit 1-13: 2008, Selected Bone Remodeling Biochemical Marker Tests
Exhibit 1-14: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
Exhibit 1-15: 2007, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier
Exhibit 1-16: 2008, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis
Exhibit 1-17: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit 1-18: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
Exhibit 1-19: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
Exhibit 1-20: Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit 1-21: 2007, Hormone Replacement Therapy and Osteoporosis Drugs Market, Share by Supplier
Exhibit 1-22: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
2. COMPANY PROFILES
2.1 The Cooper Companies, Inc.
2.2 General Electric Company
2.3 Hologic, Inc.
2.4 Inverness Medical Innovations, Inc.
2.5 Eli Lilly and Company
2.6 Merck & Company, Inc.
2.7 Novartis AG
2.8 Procter & Gamble Company
2.9 Quidel Corporation
2.10 Roche Holding AG
APPENDIX: COMPANY LISTING
- Abbott Laboratories, Inc.
- AstraZeneca PLC
- Beckman Coulter, Inc.
- Chiron Corporation
- Novartis Vaccines and Diagnostics, Inc.
- Novartis AG
- CompuMed, Inc.
- CooperSurgical, Inc./ The Cooper Companies, Inc.
- EffRx, Inc.
- Eli Lilly and Company
- Emisphere Technologies, Inc.
- FUJIFILM Medical Systems USA, Inc./FUJIFILM Corporation
- Galapagos NV
- GE Healthcare/ General Electric Company
- Genentech, Inc.
- GlaxoSmithKline PLC
- GTx, Inc.
- F. Hofmann-La Roche LTD/ Roche Holding LTD
- Hologic, Inc.
- Human Genome Sciences, Inc.
- Inverness Medical Innovations, Inc.
- Ligand Pharmaceuticals, Inc.
- Lone Oak Medical Technologies LLC
- Merck & Company, Inc.
- Nastech Pharmaceutical Company, Inc.
- Novartis AG
- Noven Pharmaceuticals, Inc.
- Novogen LTD
- Novogyne Pharmaceuticals
- NPS Pharmaceuticals, Inc.
- Nycomed International Management GmbH
- Orion Diagnostica Oy/ Orion Corporation
- Oscient Pharmaceuticals Corporation
- Pfizer, Inc.
- Procter & Gamble Company
- ProStrakan Group PLC
- Quidel Corporation
- Roche Diagnostics Corporation/ F. Hoffmann-La Roche LTD/ Roche Holding LTD
- Sectra AB
- SERVIER SA
- Takeda Pharmaceutical Company LTD
- TAP Pharmaceutical Products, Inc.
- Unigene Laboratories, Inc.
- Upsher-Smith Laboratories, Inc.
- Warner Chilcott LTD